From average daily gains and conception rates to milk production and immunity, parasites can wreak havoc on them all.1,2Whether your cattle spend their days roaming the pasture or the dry lot, your bottom line can suffer if you’re not deworming.
To provide producers with more flexible administration options, Boehringer Ingelheim has introduced a 10-L bottle of Eprinex® (eprinomectin) pour-on dewormer that can be used inverted or upright, with vented caps. This new packaging size offers added convenience for producers who are deworming large cattle herds, but don’t require the amount of product that the 20-L bottle already offers.
EPRINEX is the first dewormer to kill 39 species and stages of parasites, with up to 99.9% efficacy.3 This dewormer is convenient for processing cattle on arrival, and its nonflammable, weatherproof formula works even on long, wet hair coats. To learn more about the benefits of incorporating EPRINEX into your herd’s deworming program, visit EPRINEX.com. Remember to consult a local veterinarian when developing parasite-control protocols.
EPRINEX IMPORTANT SAFETY INFORMATION: No meat or milk withdrawal is required when used according to label. Do not use in calves intended for veal or unapproved animal species, as severe adverse reactions, including fatalities in dogs, may result.
Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. The company has pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and aims to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
EPRINEX® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2020 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-BOV-0099-2020